BCM
RUBY

Bridgeway Capital Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

Bridgeway Capital Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25,200
Closed -$4.34K – 1457
2022
Q4 		$4.34K Hold
25,200
– – ﹤0.01% 1364
2022
Q3 		$11K Buy
+25,200
New +$18.9K ﹤0.01% 1402

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Bridgeway Capital Management's RUBY Position: Q1 2023 in Review

Bridgeway Capital Management sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 25,200 shares — an estimated $4.34K sold.

Bridgeway Capital Management first reported a position in RUBY in Q3 2022 and held it in 2 quarters. The position peaked at $11K in Q3 2022. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • Bridgeway Capital Management reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • Bridgeway Capital Management sold 25,200 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $4.34K.
  • Bridgeway Capital Management first reported a position in Rubius Therapeutics, Inc in Q3 2022 and held it in 2 quarters.
  • Bridgeway Capital Management's Rubius Therapeutics, Inc position peaked at $11K in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Bridgeway Capital Management's 13F filing for Q1 2023, filed 15 May 2023.